Knowledge and Attitude among Bangladeshi Healthcare Workers regarding the Management and Infection Prevention and Control of Nipah Virus

2024-9-1

Partner Protections in HIV Cure-Related Trials Involving Analytical Treatment Interruption: Updated Toolkit to Mitigate HIV Transmission Risk

2024-9-1

Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: effect on virus-induced COX-2 expression

2024-9-1

A COMPARISON OF SOFOSBUVIR/VELPATASVIR (S/V) AND GLECAPREVIR/PIBRENTASVIR (G/P) FOR THE TREATMENT OF HCV INFECTION AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD)

2024-8-1

Existing knowledge, myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant communities

2024-6-1

Editorial Board

2024-6-1

From Awareness to Action: Unveiling Knowledge and Attitudes, and Testing Strategies to Enhance Human Papillomavirus Vaccination Uptake in Jordan

2024-6-1

Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial

2024-6-1

Editorial JVE 10.1

2024-6-1

Conference Report – Recommendations from the Forum for Collaborative Research’s symposium on hepatitis B elimination and universal hepatitis B adult vaccination in the United States

2024-6-1

Community dialogue to enhance understanding of beliefs, behaviours and barriers to care for people living with liver disease and HBV infection in KwaZulu Natal, South Africa

2024-6-1

Identifying patterns of sexual behaviors and PrEP uptake characteristics among MSM who were eligible for PrEP: A national cross-section study

2024-6-1

Vaccination against COVID-19 among healthcare workers as a cocoon strategy for people living with HIV

2024-6-1

Polio eradication in Pakistan: Hope against hope or are we near eradication?

2024-3-1

Study on immune persistence of CTN-1V strain rabies vaccine for human

2024-3-1

Highlights of the 31st Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2024 Denver, Colorado, USA

2024-3-1

Editorial JVE 10.1

2024-3-1

Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country

2024-3-1

Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa

2024-3-1

Editorial Board

2024-3-1

Engagement of AKT and ERK signaling pathways facilitates infection of human neuronal cells with West Nile virus

2024-3-1

Mass immunisation to eradicate Japanese encephalitis: Real-world evidence from Guizhou Province in 2005–2021

2024-3-1

Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientists

2024-3-1

Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study

2024-3-1

Editorial Board

2023-12-1

Antiviral activity of nitazoxanide against Morbillivirus infections

2023-12-1

Editorial JVE 9.4.

2023-12-1

The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample

2023-12-1

Population measles seroprevalence: Heterogeneity by birth-year cohort

2023-12-1

Understanding participant perspectives around HIV cure-related studies involving antiretroviral analytical treatment interruption in the United Kingdom

2023-12-1

Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand

2023-12-1

The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage

2023-12-1

Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya

2023-12-1

Patient acceptability of, and attitudes towards, hepatitis B cure research – A scoping review and identification of knowledge gaps

2023-12-1

Highlights of the HIV cure session, 19th European AIDS Clinical Society (EACS) Conference, 18-21 October 2023, Warsaw, Poland

2023-12-1

Immunomodulation with IL-7 and IL-15 in HIV-1 infection

2023-9-1

The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection

2023-9-1

Corrigendum to “HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption” [J Virus Erad 9 (2) (June 2023) 100331]

2023-9-1

Information and communication are key for hepatitis B elimination in Francophone Africa: Insights from a survey among healthcare providers

2023-9-1

Effect of high dose vitamin D3 on the HIV-1 reservoir: A pilot randomised controlled trial

2023-9-1

Editorial JVE 9.3

2023-9-1

Editorial Board

2023-9-1

To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials

2023-9-1

The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture

2023-8-29

Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV

2023-8-24

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review

2023-8-19

Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling

2023-8-12

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

2023-7-27

Antigen specificities of HIV-infected cells: A role in infection and persistence?

2023-6-1

Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform

2023-6-1